Evidence map›Paper›PMID 38986433›Full record

ArticleBrain pathology (Zurich, Switzerland)2025

Clinicopathological analysis of NEK1 variants in amyotrophic lateral sclerosis.

Olivia M Rifai, Fergal M Waldron, Danah Sleibi, Judi O'Shaughnessy, Danielle J Leighton, Jenna M Gregory

Abstract read
In one paragraph

Article in Brain pathology (Zurich, Switzerland), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Wild-typemedRxiv : the preprint server for health sciences · 2026
    Article
  6. Frontiers in aging neuroscience · 2026
    Article
  7. Review
  8. Article
  9. ALS Mutations Shift the Isoelectric Point of the KIF5A C Terminal Inducing Protein Aggregation and TDP-43 Mislocalization.The Journal of neuroscience : the official journal of the Society for Neuroscience · 2025
    Article
  10. Review
  11. Article
  12. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Olivia M RifaiCentre for Discovery Brain Sciences, University of Edinburgh, Edinburgh, UK.
Fergal M WaldronInstitute of Medical Sciences, University of Aberdeen, Aberdeen, UK.
Danah SleibiInstitute of Medical Sciences, University of Aberdeen, Aberdeen, UK.
Judi O'ShaughnessyDepartment of Chemistry, University of Edinburgh, Edinburgh, UK.
Danielle J LeightonDepartment of Chemistry, University of Edinburgh, Edinburgh, UK.
Jenna M GregoryInstitute of Medical Sciences, University of Aberdeen, Aberdeen, UK.ORCID https://orcid.org/0000-0003-3337-4079

Funding

The Physical Biology of Neurodegeneration in Sporadic Amyotrophic Lateral Sclerosis/Frontotemporal DementiaR01NS127186 · NINDS · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI HOLT, LIAM J, PHATNANI, HEMALI · 2021 to 2025
$8.2M
NINDS NIH HHS 1R01NS127186NINDS NIH HHS R01 NS127186Target ALS BB-2022-C4-L2Wellcome TrustWellcome Trust 108890/Z/15/Z
6 · The paper itself

Abstract

Many genes have been linked to amyotrophic lateral sclerosis (ALS), including never in mitosis A (NIMA)-related kinase 1 (NEK1), a serine/threonine kinase that plays a key role in several cellular functions, such as DNA damage response and cell cycle regulation. Whole-exome sequencing studies have shown that NEK1 mutations are associated with an increased risk for ALS, where a significant enrichment of NEK1 loss-of-function (LOF) variants were found in individuals with ALS compared to controls. In particular, the p.Arg261His missense variant was associated with significantly increased disease susceptibility. This case series aims to understand the neuropathological phenotypes resulting from NEK1 mutations in ALS. We examined a cohort of three Scottish patients with a mutation in the NEK1 gene and evaluated the distribution and cellular expression of NEK1, as well as the abundance of phosphorylated TDP-43 (pTDP-43) aggregates, in the motor cortex compared to age- and sex-matched control tissue. We show pathological, cytoplasmic TDP-43 aggregates in all three NEK1-ALS cases. NEK1 protein staining revealed no immunoreactivity in two of the NEK1-ALS cases, indicating a LOF and corresponding to a reduction in NEK1 mRNA as detected by in situ hybridisation. However, the p.Arg261His missense mutation resulted in an increase in NEK1 mRNA molecules and abundant NEK1-positive cytoplasmic aggregates, with the same morphologic appearance, and within the same cells as co-occurring TDP-43 aggregates. Here we show the first neuropathological assessment of a series of ALS cases carrying mutations in the NEK1 gene. Specifically, we show that TDP-43 pathology is present in these cases and that potential NEK1 LOF can either be mediated through loss of NEK1 translation or through aggregation of NEK1 protein as in the case with p.Arg261His mutation, a potential novel pathological feature of NEK1-ALS.

Indexed as

Amyotrophic Lateral SclerosisNIMA-Related Kinase 1AdultAgedDNA-Binding ProteinsFemaleHumansMaleMiddle AgedMutationMutation, MissenseDNA-Binding ProteinsNEK1 protein, humanNIMA-Related Kinase 1TARDBP protein, humanALSgeneticsNEK1neuropathologypost‐mortem

Identifiers

PMID38986433
PMCPMC11669413

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.